Filgrastim

Not to be confused with granulocyte-macrophage colony-stimulating factor or epoetin alfa.

Filgrastim
Clinical data
Trade namesNeupogen, others
Other namesXM02
Biosimilarsfilgrastim-aafi,[1] filgrastim-ayow,[2] filgrastim-sndz, filgrastim-txid[3] Accofil,[4] Biograstim,[5] Filra,[6] Fraven, Grastofil,[7] Nivestim,[8] Nivestym,[9] Nypozi,[3][10] Ratiograstim,[11] Releuko,[2] Tevagrastim, Zarxio,[12] Zarzio,[13] Zefylti[14][15]
AHFS/Drugs.comMonograph
MedlinePlusa692033
License data
Pregnancy
category
Routes of
administration		Intraveneous, subcutaneous
Drug classHematopoietic agents, colony-stimulating factors
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • Human granulocyte colony stimulating factor
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard100.167.401
Chemical and physical data
FormulaC845H1343N223O243S9
Molar mass18802.90 g·mol−1

Filgrastim, sold under the brand name Neupogen among others, is a medication used to treat low neutrophil count.[22] Low neutrophil counts may occur with HIV/AIDS, following chemotherapy or radiation poisoning, or be of an unknown cause.[22] It may also be used to increase white blood cells for gathering during leukapheresis.[22] It is given either by injection into a vein or under the skin.[22] Filgrastim is a leukocyte growth factor.[21]

Common side effects include fever, cough, chest pain, joint pain, vomiting, and hair loss.[22] Severe side effects include splenic rupture and allergic reactions.[22] It is unclear if use in pregnancy is safe for the baby.[22] Filgrastim is a recombinant form of the naturally occurring granulocyte colony-stimulating factor (G-CSF).[22] It works by stimulating the body to increase neutrophil production.[22]

Filgrastim was approved for medical use in the United States in 1991.[22] It is on the World Health Organization's List of Essential Medicines.[23][24] Filgrastim biosimilar medications are available.[22]

  1. ^ Cite error: The named reference Nivestym Drug Approval Package was invoked but never defined (see the help page).
  2. ^ a b "Releuko- filgrastim injection, solution". DailyMed. 11 March 2022. Archived from the original on 17 March 2022. Retrieved 16 March 2022.
  3. ^ a b Cite error: The named reference Nypozi FDA label was invoked but never defined (see the help page).
  4. ^ Cite error: The named reference Accofil EPAR was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference Biograstim EPAR was invoked but never defined (see the help page).
  6. ^ "Summary Basis of Decision for Filra". Drug and Health Products Portal. 3 June 2025. Retrieved 22 June 2025.
  7. ^ Cite error: The named reference Grastofil EPAR was invoked but never defined (see the help page).
  8. ^ a b Cite error: The named reference Nivestim EPAR was invoked but never defined (see the help page).
  9. ^ Cite error: The named reference Nivestym SBD was invoked but never defined (see the help page).
  10. ^ Cite error: The named reference Nypozi SBD was invoked but never defined (see the help page).
  11. ^ Cite error: The named reference Ratiograstim EPAR was invoked but never defined (see the help page).
  12. ^ Cite error: The named reference FDA_Zarxio_2015 was invoked but never defined (see the help page).
  13. ^ Cite error: The named reference Zarzio EPAR was invoked but never defined (see the help page).
  14. ^ Cite error: The named reference Zefylti EPAR was invoked but never defined (see the help page).
  15. ^ Cite error: The named reference Zefylti PI was invoked but never defined (see the help page).
  16. ^ "Filgrastim Use During Pregnancy". Drugs.com. 13 September 2018. Archived from the original on 18 December 2019. Retrieved 17 December 2019.
  17. ^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Archived from the original on 25 March 2024. Retrieved 25 March 2024.
  18. ^ "Neupogen 30 MU (0.3 mg/ml) solution for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2021. Archived from the original on 1 March 2022. Retrieved 1 March 2022.
  19. ^ "Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 4 July 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  20. ^ "Nivestim 12 MU/ 0.2 ml solution for injection/infusion - Summary of Product Characteristics (SmPC)". (emc). 18 December 2019. Archived from the original on 20 December 2019. Retrieved 20 December 2019.
  21. ^ a b Cite error: The named reference Neupogen FDA label was invoked but never defined (see the help page).
  22. ^ a b c d e f g h i j k "Filgrastim". The American Society of Health-System Pharmacists. Archived from the original on 10 May 2017. Retrieved 8 December 2016.
  23. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  24. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.